Cargando…
Successful treatment of hidradenitis suppurativa and Crohn's disease with combined guselkumab and apremilast
Autores principales: | Agud‐Dios, Manuel, Arroyo‐Andrés, Jorge, Rubio‐Muñiz, Carmen, Postigo‐Lorente, Concepción |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787683/ https://www.ncbi.nlm.nih.gov/pubmed/35904888 http://dx.doi.org/10.1111/dth.15743 |
Ejemplares similares
-
Guselkumab for hidradenitis suppurativa in a patient with concomitant Crohn’s disease: Report and systematic literature review of effectiveness and safety
por: Jørgensen, Astrid‐Helene Ravn, et al.
Publicado: (2020) -
Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers
por: Vossen, A.R.J.V., et al.
Publicado: (2018) -
Association of hidradenitis suppurativa with Crohn’s disease
por: Zhang, Meng, et al.
Publicado: (2021) -
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data
por: Martora, Fabrizio, et al.
Publicado: (2023) -
Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature
por: Garcovich, Simone, et al.
Publicado: (2020)